Lund, Sverige - Clinical Laserthermia Systems AB (publ) ("CLS" or "the company") today published its annual report for fiscal year 2023.
Clinical Laserthermia Systems AB (publ) ("CLS" or "the company") today published its annual report for fiscal year 2023. The report is available on the company's website https://clinicallaser.se/. It is also attached to this press release.
An English version of the annual report will be published on the company's website in the beginning of July.
Contact information:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 - (0)705 - 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold directly or through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se